Fulgent Genetics, Inc. FLGT Therapeutic Development — Interest Expense Nonoperating

Other segment segments

Laboratory Services

$17K+21.4%

Similar metrics at other companies

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Interest Expense, Nonoperating

$1.75M+101%

GKOSDevelopment And Commercialization Of Ophthalmic Therapies — Interest Expense Nonoperating

$1.13M-3.3%

CAPRInterest Expense, Nonoperating

$761.43K—

CVCOFinancial services — Interest Expense, Nonoperating

$0—

HRMYRare Neurological Diseases — Interest Expense Nonoperating

$3.23M-15.7%

NHCInpatient Services — Interest Expense Nonoperating

$269K-87.2%

Other financials

Income statement

See full

Revenue$71.1M-3.2%

Gross profit$21.5M-24.2%

Operating income-$34.6M-74.9%

Net income-$24.8M-115%

EPS (diluted)-$0.80-116%

Balance sheet

See full

Cash & equivalents$23.4M-65.2%

Total debt$8.2M+40.5%

Total equity$1.0B-6.9%

Total assets$1.2B-4.1%

Cash flow

See full

Operating cash flow$7.1M+260%

CapEx$5.2M+10.3%

Free cash flow$1.9M+121%

Valuation

See full

Market cap$552.11M-7.1%

Enterprise value$536.92M+0.7%

P/S1.7×-0.3×

Profitability

See full

Gross margin38.7%-0.1pp

Operating margin-33.1%+17.4pp

Net margin-23%+43.3pp

FCF margin-36.9%—

Returns & leverage

See full

Return on equity-6.8%+48.2pp

Debt / equity0×0.0×

Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — interest expense nonoperating.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s therapeutic development — interest expense nonoperating?: Fulgent Genetics, Inc. (FLGT) reported therapeutic development — interest expense nonoperating of $0 in Q1 2026.
What does therapeutic development — interest expense nonoperating mean?: This represents interest costs incurred on debt or financing arrangements that are not related to the core operating activities of the therapeutic development segment. It is used to assess the impact of the segment's financing structure on its overall financial health.